Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19

We report in vivo selection of a severe acute respiratory syndrome coronavirus 2 spike mutation (Q493R) conferring simultaneous resistance to bamlanivimab and etesivimab. This mutation was isolated from a patient who had coronavirus disease and was treated with these drugs.

Detalles Bibliográficos
Autores principales: Focosi, Daniele, Novazzi, Federica, Genoni, Angelo, Dentali, Francesco, Gasperina, Daniela Dalla, Baj, Andreina, Maggi, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462334/
https://www.ncbi.nlm.nih.gov/pubmed/34314668
http://dx.doi.org/10.3201/eid2710.211538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462334/
https://www.ncbi.nlm.nih.gov/pubmed/34314668
http://dx.doi.org/10.3201/eid2710.211538

Ejemplares similares